Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Panel Gives Blessing to 1st Triple Combo Therapy for Asthma; Humira Biosimilar Also in Line for June OK
May 29, 2020
- Japan Sets 30 Day Prescription Limit for Shionogi’s ADHD Med Vyvanse
May 29, 2020
- 145.5 Billion Yen Allocated for COVID-19 Vaccine Production in Second Extra Budget: MHLW
May 29, 2020
- GSK’s Cost-Effectiveness Analysis for Trelegy Delayed, First Product under Full CEA Scheme
May 28, 2020
- Chuikyo Wary about Off-Year Price Survey amid COVID-19, Industry Officials Stress Concerns
May 28, 2020
- Japan Drops May-End Goal for Avigan’s COVID-19 Approval
May 27, 2020
- Council to Discuss Medical Needs for Additional Indications for Antiemetics Ondansetron, Granisetron
May 27, 2020
- Japan’s First Humalog Biosimilar to Join NHI Price List on May 27
May 26, 2020
- Final Report from Govt’s All-Generation Social Security Council to Be Delayed until Year-End
May 26, 2020
- June Approval Likely for Entresto as It Clears Key Panel; HFpEF Use OK’ed Too
May 25, 2020
- Panel OKs Ofev for PF-ILD; Label Expansion for Xtandi/Erleada, Prevenar and More
May 25, 2020
- MSD’s 9-Valent HPV Vaccine Now in Line for June Approval; Eyes on Its Possible Inclusion in National Immunization Program
May 25, 2020
- PMDA Reviewing Safety Risks for Avastin, Memary
May 25, 2020
- AMED to Fund 4 Company-Led COVID-19 Vaccine Development Projects
May 25, 2020
- Avigan Not Yet Filed in Japan, but Govt Still Seeks Approval by Month-End: Kato
May 25, 2020
- Add MSD’s 9-Valent HPV Vaccine to National Immunization Program If Approved: Lawmakers
May 21, 2020
- Label Revisions Ordered for 15 Insulins, Erleada, Faslodex
May 20, 2020
- MHLW Adds Veklury in Updated COVID-19 Treatment Guide
May 20, 2020
- LDP Lawmakers Call for Environment to Facilitate Vaccine Development
May 20, 2020
- Check Latest Info and Make Careful Decision on Veklury Use: PMDA Review Report
May 19, 2020
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…